RU2496514C2 - Применение пэгилированных интерферонов типа iii для лечения гепатита с - Google Patents

Применение пэгилированных интерферонов типа iii для лечения гепатита с Download PDF

Info

Publication number
RU2496514C2
RU2496514C2 RU2010154092/15A RU2010154092A RU2496514C2 RU 2496514 C2 RU2496514 C2 RU 2496514C2 RU 2010154092/15 A RU2010154092/15 A RU 2010154092/15A RU 2010154092 A RU2010154092 A RU 2010154092A RU 2496514 C2 RU2496514 C2 RU 2496514C2
Authority
RU
Russia
Prior art keywords
pegylated
interferon
polypeptide
hepatitis
weeks
Prior art date
Application number
RU2010154092/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010154092A (ru
Inventor
Диана Ф. ХОСМАН
Майкл Г. ДОДДС
Original Assignee
Займоджинетикс, Инк.
Бристоль-Мейерз Квибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Займоджинетикс, Инк., Бристоль-Мейерз Квибб Компани filed Critical Займоджинетикс, Инк.
Publication of RU2010154092A publication Critical patent/RU2010154092A/ru
Application granted granted Critical
Publication of RU2496514C2 publication Critical patent/RU2496514C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2010154092/15A 2008-06-05 2009-06-05 Применение пэгилированных интерферонов типа iii для лечения гепатита с RU2496514C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5923708P 2008-06-05 2008-06-05
US61/059,237 2008-06-05
US10945508P 2008-10-29 2008-10-29
US61/109,455 2008-10-29
US16776309P 2009-04-08 2009-04-08
US61/167,763 2009-04-08
PCT/US2009/046451 WO2009149377A1 (en) 2008-06-05 2009-06-05 Use of pegylated type iii interferons for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
RU2010154092A RU2010154092A (ru) 2012-07-20
RU2496514C2 true RU2496514C2 (ru) 2013-10-27

Family

ID=41020837

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010154092/15A RU2496514C2 (ru) 2008-06-05 2009-06-05 Применение пэгилированных интерферонов типа iii для лечения гепатита с

Country Status (8)

Country Link
US (1) US20110165121A1 (cg-RX-API-DMAC7.html)
EP (1) EP2296691A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011522834A (cg-RX-API-DMAC7.html)
CN (2) CN102099051A (cg-RX-API-DMAC7.html)
AU (1) AU2009255994B2 (cg-RX-API-DMAC7.html)
CA (1) CA2727026A1 (cg-RX-API-DMAC7.html)
RU (1) RU2496514C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009149377A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678332C1 (ru) * 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271786A1 (en) 2000-06-30 2002-01-14 Zymogenetics Inc. Interferon-like protein zcyto21
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
US7157559B2 (en) 2003-08-07 2007-01-02 Zymogenetics, Inc. Homogeneous preparations of IL-28 and IL-29
WO2005097165A2 (en) 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2011098644A2 (es) 2010-02-09 2011-08-18 Proyecto De Biomedicina Cima, S.L. Composiciones para el tratamiento de enfermedades infecciosas y tumorales
WO2012031763A1 (en) * 2010-09-08 2012-03-15 Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013029062A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Co., Ltd Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
BR112014004302A2 (pt) * 2011-08-25 2017-06-20 Nanogen Pharmaceutical Biotechnology conjugado, composição farmacêutica, processo para preparar um conjugado, métodos para inibir a proliferação de uma célula cancerosa, para tratar um distúrbio, e para tratar um paciente
AU2013201406B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088408A1 (es) 2011-10-21 2014-05-28 Abbvie Inc Metodos para el tratamiento de hcv
CN102533840A (zh) * 2011-12-13 2012-07-04 江南大学 毕赤酵母制备人白细胞介素29成熟肽的方法
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
CN104045704B (zh) * 2013-03-11 2016-08-10 中国医学科学院基础医学研究所 PEG化重组人IFN-λ1、其制备方法和用途
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
JP6730926B2 (ja) * 2014-01-08 2020-07-29 プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
RU2016148364A (ru) * 2014-05-12 2018-06-13 Конатус Фармасьютикалз, Инк. Лечение осложнений хронического заболевания печени
US11759500B2 (en) * 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
JP2019107021A (ja) * 2019-03-05 2019-07-04 プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法
WO2020193459A1 (en) 2019-03-25 2020-10-01 F. Hoffmann-La Roche Ag Solid forms of a compound of hbv core protein allosteric modifier
US20220370447A1 (en) * 2019-09-20 2022-11-24 Hoffmann-La Roche Inc. Method of treating hbv infection using a core protein allosteric modulator
WO2021216801A1 (en) * 2020-04-22 2021-10-28 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037995A2 (en) * 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
WO2005097165A2 (en) * 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
WO2007012033A2 (en) * 2005-07-20 2007-01-25 Zymogenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
EA009783B1 (ru) * 2002-01-18 2008-04-28 Байоджен Айдек Ма Инк. Полиалкиленгликоль с остатком для конъюгации биологически активного соединения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271786A1 (en) * 2000-06-30 2002-01-14 Zymogenetics Inc. Interferon-like protein zcyto21
US7038032B2 (en) * 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US7157559B2 (en) * 2003-08-07 2007-01-02 Zymogenetics, Inc. Homogeneous preparations of IL-28 and IL-29
CA2574564C (en) * 2004-07-29 2013-04-16 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer and autoimmune disorders
US20070020227A1 (en) * 2005-07-20 2007-01-25 Sheppard Paul O Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
ATE491722T1 (de) * 2005-10-04 2011-01-15 Zymogenetics L L C Herstellung und reinigung von il-29

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009783B1 (ru) * 2002-01-18 2008-04-28 Байоджен Айдек Ма Инк. Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
WO2004037995A2 (en) * 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
WO2005097165A2 (en) * 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
WO2007012033A2 (en) * 2005-07-20 2007-01-25 Zymogenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOLEWSKA B. et al. Interferon alpha, gamma, omega before and during treatment of chronic hepatitis С with pegylated interferon alpha and ribavirin. // Przegl Epidemiol. 2007; 61(4):755-63. Найдено из Интернета [онлайн] на сайте http://www.ncbi.nlm.nih.gov/pubmed/18572508. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2678332C1 (ru) * 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
WO2019050437A1 (ru) 2017-09-08 2019-03-14 Общество С Ограниченной Ответственностью"Саентифик Фьючер Менеджмент" Пегилированный интерферон лямбда при пероральном применении и способ его получения

Also Published As

Publication number Publication date
WO2009149377A1 (en) 2009-12-10
EP2296691A1 (en) 2011-03-23
JP2011522834A (ja) 2011-08-04
US20110165121A1 (en) 2011-07-07
AU2009255994A1 (en) 2009-12-10
RU2010154092A (ru) 2012-07-20
CN102099051A (zh) 2011-06-15
AU2009255994B2 (en) 2014-07-17
AU2009255994A2 (en) 2011-02-17
CA2727026A1 (en) 2009-12-10
CN103536906A (zh) 2014-01-29

Similar Documents

Publication Publication Date Title
RU2496514C2 (ru) Применение пэгилированных интерферонов типа iii для лечения гепатита с
EP0567566B1 (en) Methods for treating tumor necrosis factor mediated diseases
TW570802B (en) Improved interferon polymer conjugates
TWI406672B (zh) 生物效力增進的β干擾素聚合物共軛體
TWI364295B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
Ceaglio et al. Novel long-lasting interferon alpha derivatives designed by glycoengineering
US8597635B2 (en) Interferon alpha-2B modified by polyethylene glycol and methods of preparation thereof
US20060029573A1 (en) Pegylated interferon alpha-1b
EP1037657A4 (en) ALPHA INTERFERON-POLYMER CONJUGATES WITH INCREASED BIOLOGICAL EFFECTIVENESS AND METHOD FOR THE PRODUCTION THEREOF
US8597634B2 (en) Interferon alpha-2a modified by polyethylene glycol and methods of preparation thereof
US20090214472A1 (en) Interferon-beta polymer conjugates
CN103228792A (zh) PEG-干扰素λ1结合物
JP2006519235A (ja) ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
WO2005038056A1 (en) Combination therapy for the treatment of viral diseases
RU2392963C2 (ru) Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
AU784768B2 (en) Methods for treating cytokine mediated diseases
JP2004182683A (ja) 新規な炎症性疾患改善剤
WO2013029062A1 (en) Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same